Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA.
BMC Womens Health. 2012 Jan 6;12:1. doi: 10.1186/1472-6874-12-1.
Health outcomes could be improved if women at high risk for osteoporotic fracture were matched to effective treatment. This study determined the extent to which treatment for osteoporosis/osteopenia corresponded to the presence of specific risk factors for osteoporotic fracture.
This retrospective analysis of the United States 2007 National Health and Wellness Survey included women age ≥ 40 years who reported having a diagnosis of osteoporosis (69% of 3276) or osteopenia (31% of 3276). Patients were stratified by whether they were or were not taking prescription treatment for osteoporosis/osteopenia. Using 34 patient characteristics as covariates, logistic regression was used to determine factors associated with treatment.
Current prescription treatment was reported by 1800 of 3276 (54.9%) women with osteoporosis/osteopenia. The following factors were associated with receiving prescription treatment: patient-reported diagnosis of osteoporosis (versus osteopenia); previous bone mineral density test; ≥ 2 fractures since age 50; older age; lower body mass index; better physical functioning; postmenopausal status; family history of osteoporosis; fewer comorbidities; prescription insurance coverage; higher total prescription count; higher ratio of prescription costs to monthly income; higher income; single status; previous visit to a rheumatologist or gynecologist; and 1 or 2 outpatient visits to healthcare provider (vs. none) in the prior 6 months. Glucocorticoid, tobacco, and daily alcohol use were risk factors for fracture that were not associated with treatment.
There is a mismatch between those women who could benefit from treatment for osteoporosis and those who are actually treated. For example, self-reported use of glucocorticoids, tobacco, and alcohol were not associated with prescription treatment of osteoporosis. Other clinical and socioeconomic factors were associated with treatment (e.g. prescription drug coverage and higher income) or not (e.g. comorbid osteoarthritis and anxiety) and could be opportunities to improve care.
如果能将患有骨质疏松性骨折高危风险的女性与有效的治疗方法相匹配,那么她们的健康结果可能会得到改善。本研究旨在确定针对骨质疏松症/骨量减少症的治疗与骨质疏松性骨折特定风险因素的存在之间的相关性。
本项对美国 2007 年国家健康与健康调查的回顾性分析纳入了报告患有骨质疏松症(3276 例中的 69%)或骨量减少症(3276 例中的 31%)的年龄≥40 岁的女性患者。根据是否服用骨质疏松症/骨量减少症的处方药物,将患者分为治疗组和未治疗组。使用 34 项患者特征作为协变量,通过逻辑回归分析确定与治疗相关的因素。
在 3276 例骨质疏松症/骨量减少症患者中,有 1800 例(54.9%)报告正在服用处方药物。以下因素与接受处方治疗相关:患者报告的骨质疏松症诊断(而非骨量减少症);既往进行过骨密度检测;50 岁后发生≥2 次骨折;年龄较大;体重指数较低;身体功能较好;绝经后状态;骨质疏松症家族史;合并症较少;处方保险覆盖范围;总处方数量较高;处方费用与月收入的比例较高;收入较高;单身状态;既往看风湿病医生或妇科医生;以及过去 6 个月内 1 次或 2 次就诊于医疗保健提供者(而非无就诊)。糖皮质激素、烟草和每日饮酒是骨折的危险因素,但与治疗无关。
在那些可能受益于骨质疏松症治疗的女性和实际接受治疗的女性之间存在不匹配的情况。例如,自我报告使用糖皮质激素、烟草和酒精与骨质疏松症的处方治疗无关。其他临床和社会经济因素与治疗(如处方药物覆盖范围和较高收入)或不治疗(如合并骨关节炎和焦虑症)相关,这可能是改善治疗的机会。